M
Description
Mid-sized CDMO launched in April 2025, headquartered in UK with 13 manufacturing sites across France, Spain and Sweden. Born from the merger of Synerlab Group (Strasbourg CDMO specialising in lyophilisation and liquid sterile dosage forms) and seven Recipharm manufacturing sites (oral solid, semi-solid and liquid). Backed by Blue Wolf Capital Partners. Offers services from drug development to manufacturing of sterile and niche dosage forms.